

Intralipid 20%

Cat. No.:	HY-131370B		
CAS No.:	68890-65-3		
Target:	Biochemical Assay Reagents		
Pathway:	Others		
Storage:	Pure form	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

Intralipid 20%

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (Need ultrasonic)
----------	------------------------------------

BIOLOGICAL ACTIVITY

Description	Intralipid 20% is a safe fat emulsion that can be used as a nutritional supplement. Intralipid 20% effectively inhibits the opening of the mitochondrial permeability transition pore, effectively protecting the heart from ischaemia-reperfusion injury and has some potential to modulate the innate immune response ^{[1][2]} .
In Vitro	Intralipid 20% (0-0.2 mg/mL) specifically protects immune cells from paclitaxel, but has no effect on tumor cells ^[1] . Intralipid 20% (0-0.2 mg/mL, 3 days) promotes polarisation of M0, M1 and M2 macrophages to an M1-like phenotype ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Intralipid (2 g/kg) does not affect phagocytosis and may promote macrophage polarization to the M1 phenotype, as observed in breast cancer tumor sections from Balb/c mice ^[1] . Intralipid pretreatment promotes the accumulation of paclitaxel in tumour tissue and induces higher levels of apoptosis in tumour cells. Increased distribution of paclitaxel in mouse RES organs and enhanced inhibition of tumour growth ^[1] . Intralipid (5 mL/kg) is more effective than cyclosporin-A in protecting the heart from I/R injury in SD rats, reducing the size of myocardial infarction by approximately 40% ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Res Sq. 2024 Sep 17.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Jingyuan Li, et al. Intralipid, a clinically safe compound, protects the heart against ischemia-reperfusion injury more efficiently than cyclosporine-A. Anesthesiology. 2012 Oct;117(4):836-46.

[2]. Yen-Ju Chen, et al. Impacts of Intralipid on Nanodrug Abraxane Therapy and on the Innate Immune System. Sci Rep. 2020 Feb 18;10(1):2838.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA